Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License...
United States United Kingdom Saudi Arabia Jason Zhu Prnewswire Shanghai Henlius Biotech Inc Jacobson Group
Source: prnewswire.com